Experts at 2017 China Medicine Summit Forum

Wei Yuquan, academician of Chinese Academy of Sciences, director of clinical oncology center of West China Hospital and director of National Key Laboratory of Biotherapy, former vice president of Sichuan University Wei Yuquan, Professor of oncology, academician of Chinese Academy of Sciences, director of clinical oncology center of West China Hospital and director of National Key Laboratory of Biotherapy, former vice president of Sichuan University, President of China Pharmaceutical Biotechnology Association, director of national biotherapy Collaborative Innovation Center, director of national comprehensive new drug research and development technology platform, Ministry of science and technology "973" Chief scientist of the project, director of innovation research group of NSFC; CO editor of signal transmission and targeted therapy, deputy editor of human gene therapy, deputy editor of current molecular medicine, and editorial board member of current cancer drug targets in Asia The second batch of specially appointed professors of the "Yangtze River scholars Award Program" of the Ministry of education, the first and second level candidates of the "one million talents project" of the state, the member of the subject expert group of biotechnology drugs in the field of biology and medicine in the 12th Five Year Plan "863", the former vice president of the Chinese Medical Association, and the former executive vice director of the biomedical Department of the science and Technology Committee of the Ministry of education Speech title: innovative drug research and development and China's opportunities Professor Chen Shu professor of China Pharmaceutical University, vice president of School of Science [summit person] Chen Shu: Interpretation of 2017 new drug research and development trends and R & D strength ranking list Professor Lu Tao doctoral supervisor, vice president of China Pharmaceutical University Professor Lu Tao obtained his Ph.D in pharmaceutical chemistry from China Pharmaceutical University in 2001, was employed as a professor in 2004, and as a doctoral supervisor in 2006; he was appointed as the deputy director of the foundation department in October 2000, the director of the foundation department in February 2003, the dean of the school of Science in May 2012, and the Standing Committee member and vice president of the CPC China Pharmaceutical University Committee in July 2013 Currently, he is the vice chairman of the National Steering Committee for postgraduate education of pharmaceutical degree, the communication evaluation expert of the Ministry of life sciences of the national foundation of China, the evaluation expert of the drug price demonstration center of the national development and Reform Commission, the undergraduate teaching evaluation expert of the Ministry of education, and the member of the Council of Jiangsu Chemical Society and organic chemistry Professional Committee Executive editor of pharmaceutical progress, editorial board member of Journal of China Pharmaceutical University Main research fields: molecular design and synthesis of new drugs, computer-aided drug design, organic synthetic chemistry, drug biostatistics and computational pharmacy He has presided over and completed a number of national, provincial and ministerial projects At present, the research group is working on 10 projects under the National Natural Science Foundation, and the independently developed antitumor compounds are transferred to Shanghai Fosun Pharmaceutical Industry Co., Ltd at a price of 50 million yuan More than 80 SCI research papers have been published 13 doctoral students and 85 master students have been supervised At present, there are 11 doctoral students and 42 postgraduate students Report title: thinking about the orientation of universities in the research of innovative drugs -- starting from the development of anti leukemia clinical new drug fn-1501, Professor Li Xiaohui, the expert of the first sub conference, the doctoral supervisor, the director of the Institute of medicine of the Army Medical University of the people's Liberation Army, the director of Chongqing efficacy evaluation center, and the 2015 person of scientific Chinese [summit person] Li Xiaohui: the current situation, problems and solutions of cardiovascular drug research and development Professor Zhang Zhirong (supervisor), Professor of Sichuan University, director of the Key Laboratory of the Ministry of education of targeted drugs and drug delivery system, and President of the former Chinese Academy of Western Medicine [summit person] Zhang Zhirong: the role of drug delivery system in new drug research and development and preparation innovation strategy Professor Hou Yu Hou Yu, Professor of Hebei University of science and technology and President of Chongqing Kangzhou pharmaceutical big data development and Application Research Institute [summit person]: Construction and solution of drug patent protection network Professor He Yun, expert of national thousand talents plan, President of Chongqing University School of medicine, President of Chongqing University Innovation drug research center [summit person] Professor He Yun: new ideas of global natural drug research and development Shaoying Dr (moderator of the Seminar) summit dialogue between vice president of Fosun Pharmaceutical, director of R & D center and former director of Review Department of CFDA drug review center: At present, the transformation and upgrading has developed to the critical stage involving the life and death of enterprises, not just the concept It has become one of the important strategies on the road of enterprise transformation to deepen the internationalization and formulate the corresponding strategies and strategies, which are paid more and more attention by enterprises In line with the general trend of the industry development, this dialogue link "the internationalization of Chinese pharmaceutical enterprises" invites senior industry figures to discuss policies and regulations, patent challenges, R & D layout under the internationalization trend, business strategies, etc., and discuss the direction and path of the internationalization of Chinese pharmaceutical enterprises Lei Huangshu, an expert of "hundred talents plan" of Chongqing municipal government, former senior researcher of Pfizer, GlaxoSmithKline and Novartis [summit figure], Lei Huangshu: design and synthesis of IAP inhibitors for cancer treatment, Dr Zhang natural (host of the conference), expert of drug price review of national development and Reform Commission, and senior expert of pharmaceutical operation and M & A Zhang Ran, M.D., expert of drug price evaluation of national development and Reform Commission, specially invited vice president of China Chemical Pharmaceutical Industry Association and director of special committee of policies and regulations, successively served as executives of several pharmaceutical groups such as Shangyao and Shenwei, studied in the UK in the early years, and engaged in pharmaceutical work in the United States Speech title: new policy of pharmaceutical research and development to promote industrial integration, Dr Lu Laichun, Professor of Military Medical University of the PLA army, former director of organization office of Daping Hospital Affiliated to the PLA Army Medical University [summit person], Lu Laichun: verification of clinical trials of drugs after the new policy of new drugs, Deng Wan and Xi'an YANGSEN, deputy director of pharmaceutical registration Deng Wanhe has worked in Novartis, Takeda, PPD consulting and other companies, and has been engaged in drug registration for nearly 10 years Degree in medicine and computer science Speech title: data application in drug registration Li Junde, professor level senior engineer, deputy director of North China Pharmaceutical R & D center [summit person] Li Junde: improvement of R & D data integrity management under the new policy of registration Dr Gou Xiaojun, director of Sichuan Antibiotic Industry Research Institute, director of Key Laboratory of drug and food homologous plant resources development, Sichuan University [summit person] Gou Xiaojun: the current situation and Countermeasures of anti drug resistant TB drug research and development Guo pengaister (Chengdu) bio Pharmaceutical Co., Ltd chairman, Sichuan Province "special expert" [summit person] Guo Peng: API licensed production and cdmo under the system of drug listing license holder Dr Li Yingji, general manager of Beijing aisiyipu Bio Technology Co., Ltd [summit person] Li Yingji: how to identify the cardiotoxicity of compounds in the early stage and reduce the risk of new drug research and development Li kechun (host of technology transfer) Mingxin, partner of China Growth Fund and expert of national thousand talents program review technology transfer: In recent years, the State Food and drug administration has formulated a series of management processes and new policies to integrate technical resources and promote specialized and large-scale production of the pharmaceutical industry, including: Mah listing license holder system allows the holder to entrust production and sell drugs on his own or by Commission; the clinical approval / production approval transfer series process of drugs will be released soon to lay the foundation for a new round of technology transactions in the whole pharmaceutical industry At this meeting, many enterprises have applied for the project roadshow recommendation for their process technology / clinical approval / production approval, and look forward to reaching technical transactions through this meeting Li Tianquan, senior engineer, co-founder of yaozhi.com and President of Yaozhi elite club [summit person] Li Tianquan: chief pharmacist Wu yongpei, expert in the second sub conference of big data application in the field of pharmaceutical research and development, honorary director of Pharmaceutical Management Professional Committee of China Hospital Association Wu yongpei, director of the pharmaceutical management research department of the Hospital Management Research Institute of the Ministry of health, and an expert enjoying the special government allowance of the State Council, has been rated as the advanced worker of the hospital and the Excellent Communist Party member of the Ministry of health and the central state organ for many times He has been engaged in the research and practice of clinical pharmacy and hospital pharmacy management for nearly 60 years, and has participated in the drafting of many hospital pharmacy laws and regulations In the past 20 years, he has written about 80 papers, edited 7 monographs and participated in the compilation of 15 At present, he is also the honorary chairman of the pharmaceutical management professional committee of China Hospital Association, the chairman of the expert committee of clinical pharmacist system of the Ministry of health, the vice chairman of the expert committee of rational drug use of the Ministry of health, the member of the expert committee of clinical pathway of the Ministry of health, and the vice chairman of the China group of international network of rational drug use Speech title: Chen Ji, director of the Department of pharmacy, the First Affiliated Hospital of Xinjiang Medical University Chen Ji, executive member of Secretary General of Pharmaceutical Management Professional Committee of Xinjiang Hospital Association, (INRUD) member of China Center Group / PIVAS rational drug use group, member of PIVAS professional group of Pharmaceutical Management Professional Committee of China Hospital Association, member of Expert Committee of Xinjiang clinical safe drug use monitoring network, and supervision expert of Xinjiang Medical Institution intravenous drug use allocation center He has undertaken National Natural Science Foundation, national high technology research and development plan (863 plan), high technology research and development plan project of the autonomous region and many research projects of Medical University; won many awards such as science and technology progress award of the autonomous region, medical science and technology award of Xinjiang, pharmaceutical science and technology award of Xinjiang; won three national invention patents, two utility patents, undergraduate course of University and Postgraduate courses such as clinical pharmacology, therapeutic drug monitoring, pharmacoeconomics, clinical application of antibacterial drugs, modern hospital pharmacy work technology, etc., participated in the establishment of PIVAS acceptance standards in Xinjiang; edited and participated in the compilation of 4 monographs, and published more than 20 papers in recent years Lecture Title: formulation and Reflection on the examination standard of intravenous medication orders, Professor Mi Wenjie, master supervisor, pharmaceutical department, Qilu general hospital, Shandong University Mi Wenjie, contact person of INRUD / China Center Group / PIVAS rational drug use group, deputy group leader and Secretary of PIVAS professional group of Pharmaceutical Management Professional Committee of China Hospital Association, acceptance management expert of national intravenous drug dispensing center, professional committee and chairman of intravenous infusion nursing of Shandong Nursing Association, professional committee and member of intravenous infusion nursing of Chinese Nursing Association, Shandong medicine Institute of intravenous drug safety deployment professional committee, vice chairman, responsible for Shandong Pharmaceutical Association intravenous drug safety deployment Professional Committee nursing branch work He has published more than 20 papers in core journals, 6 monographs and 2 medical audio-visual textbooks, and participated in many national and provincial scientific research projects Speech title: quality control of PIVAS Professor Zhang Jianzhong, deputy director and chief pharmacist / Professor of Pharmaceutical Department of Zhongshan Hospital Affiliated to Fudan University, has long been engaged in basic pharmaceutical work, production management, quality control and research and development of new pharmaceutical preparations, construction of intravenous drug dispensing center, PIVAS pharmaceutical services, information management of safe drug use, etc In the past 10 years, many practices and researches have been carried out in the aspects of safety management of clinical infusion, rational use of antibiotics, stability research of parenteral nutrition, safety of cytotoxic drug preparation, etc Lecture Title: PIVAS operation from the perspective of pharmaceutical care Professor Bao Jian'an, director of the pharmaceutical department, chief pharmacist / Professor, master's supervisor of the First Affiliated Hospital of Suzhou University, Bao Jian'an, has been engaged in the practice and management of hospital pharmacy for a long time, has rich experience and innovation in pharmacy information automation and pharmaceutical care, and participates in the rational and safe use of hospital drugs